Last reviewed · How we verify

Olivia Cardenas-Trowers, M.D. — Portfolio Competitive Intelligence Brief

Olivia Cardenas-Trowers, M.D. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bladder instillation WITHOUT triamcinolone acetonide Bladder instillation WITHOUT triamcinolone acetonide phase 3 Urology
Bladder instillation WITH triamcinolone acetonide Bladder instillation WITH triamcinolone acetonide phase 3 Corticosteroid (intravesical instillation) Glucocorticoid receptor Urology / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Olivia Cardenas-Trowers, M.D.:

Cite this brief

Drug Landscape (2026). Olivia Cardenas-Trowers, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/olivia-cardenas-trowers-m-d. Accessed 2026-05-16.

Related